We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...

Please provide your email address to receive an email when new articles are posted on . XEN1101 is a novel small-molecule selective Kv7.2/Kv7.3 potassium channel opener. A 25 mg dose of XEN1101 ...

LANDOVER, Md., April 24, 2018 (GLOBE NEWSWIRE) -- The Epilepsy Foundation today announced the launch of a new Human Epilepsy Project study of focal seizures to better understand the long-term ...

Early detection of focal epilepsy may reduce the amount of motor vehicle accidents caused by seizures while driving. The prevalence of seizures while driving (SzWD) prior to diagnosis in people with ...

Prior to being diagnosed with epilepsy, 5% of people with a type of epilepsy called focal epilepsy had a seizure while driving, according to a new study published in the June 7, 2023, online issue of ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. A positive readout of a Rapport Therapeutics seizure medicine in a ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...